December 10, 2025
A noninvasive blood test to detect genetic material shed by tumors may help clinicians identify adverse events related to treatment with immune checkpoint inhibitor drugs, investigators at the Johns Hopkins Kimmel Cancer Center have found.
In a Dec. 11 letter to the editor of the New England Journal of Medicine, the researchers describe how they measured cell-free DNA to identify tissue damage to nine organs in a study involving 14 patients with solid tumors who received immune checkpoint inhibitor therapy, a treatment that helps boost the immune system's ability to attack cancer.
https://medicalxpress.com/news/2025-12-cell-free-dna-adverse-events.html